89bio Inc (ETNB)
89bio, Inc., headquartered in San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver and cardio-metabolic diseases. Their primary product, pegozafermin, is a modified analog of a growth factor being developed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company was established in 2018.
Company Info
Highlights
$1.62B
-$2.96
-$21.00K
-$244.16M
$5.99 - $16.63
$30.67
8.87%
2.61
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in 89bio Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
89bio Inc had a return of 44.50% year-to-date (YTD) and 14.26% in the last 12 months.
ETNB
44.50%
79.08%
26.97%
14.26%
-19.68%
N/A
^GSPC (Benchmark)
4.46%
2.46%
9.31%
23.49%
13.03%
11.31%
Monthly Returns
The table below presents the monthly returns of ETNB, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 22.76% | 44.50% | |||||||||||
| 2024 | -11.37% | 15.86% | 1.48% | -26.89% | -7.17% | 1.39% | 14.36% | 3.71% | -22.11% | 5.14% | 15.55% | -13.01% | -29.99% |
| 2023 | -8.25% | 16.61% | 11.82% | 4.92% | 14.08% | 3.95% | -16.41% | 8.21% | -9.92% | -52.07% | 8.65% | 38.93% | -12.25% |
| 2022 | -54.93% | -21.39% | -18.57% | -42.44% | 38.71% | 6.98% | 10.25% | 25.63% | 29.82% | 64.94% | -16.23% | 59.13% | -2.60% |
| 2021 | -16.70% | 20.99% | -3.58% | 11.02% | -28.11% | -1.06% | -16.26% | 18.20% | 5.83% | -10.16% | -24.94% | -1.06% | -46.37% |
| 2020 | 1.64% | 33.50% | -29.21% | -6.89% | 9.57% | -22.63% | 52.43% | 26.73% | -33.35% | -9.74% | 16.62% | -9.77% | -7.30% |
| 2019 | 50.34% | -15.93% | 26.39% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ETNB is 53, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for 89bio Inc (ETNB) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the 89bio Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the 89bio Inc was 95.00%, occurring on May 9, 2022. The portfolio has not yet recovered.
The current 89bio Inc drawdown is 72.95%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95% | Mar 3, 2020 | 552 | May 9, 2022 | — | — | — |
| -26.29% | Nov 27, 2019 | 21 | Dec 27, 2019 | 21 | Jan 29, 2020 | 42 |
| -23.05% | Jan 30, 2020 | 3 | Feb 3, 2020 | 10 | Feb 18, 2020 | 13 |
| -10.51% | Feb 26, 2020 | 2 | Feb 27, 2020 | 2 | Mar 2, 2020 | 4 |
| -8.76% | Feb 20, 2020 | 2 | Feb 21, 2020 | 2 | Feb 25, 2020 | 4 |
Volatility
Volatility Chart
The current 89bio Inc volatility is 30.30%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for 89bio Inc.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |